AU2003257588A1 - REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS - Google Patents

REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS

Info

Publication number
AU2003257588A1
AU2003257588A1 AU2003257588A AU2003257588A AU2003257588A1 AU 2003257588 A1 AU2003257588 A1 AU 2003257588A1 AU 2003257588 A AU2003257588 A AU 2003257588A AU 2003257588 A AU2003257588 A AU 2003257588A AU 2003257588 A1 AU2003257588 A1 AU 2003257588A1
Authority
AU
Australia
Prior art keywords
prostaglandins
kinase inhibitor
rho kinase
glaucoma
remedy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003257588A
Other languages
English (en)
Inventor
Hideaki Hara
Takeshi Matsugi
Tadashi Nakajima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of AU2003257588A1 publication Critical patent/AU2003257588A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2003257588A 2002-08-29 2003-08-29 REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS Abandoned AU2003257588A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002-250223 2002-08-29
JP2002250223 2002-08-29
PCT/JP2003/011004 WO2004019951A1 (ja) 2002-08-29 2003-08-29 Rhoキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤

Publications (1)

Publication Number Publication Date
AU2003257588A1 true AU2003257588A1 (en) 2004-03-19

Family

ID=31972618

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003257588A Abandoned AU2003257588A1 (en) 2002-08-29 2003-08-29 REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS

Country Status (11)

Country Link
US (4) US20050245509A1 (ko)
EP (2) EP2314299A1 (ko)
JP (1) JP5174777B2 (ko)
KR (2) KR101160780B1 (ko)
CN (1) CN100425241C (ko)
AT (1) ATE546143T1 (ko)
AU (1) AU2003257588A1 (ko)
CA (1) CA2496797C (ko)
ES (1) ES2382733T3 (ko)
TW (2) TWI350170B (ko)
WO (1) WO2004019951A1 (ko)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100425241C (zh) * 2002-08-29 2008-10-15 参天制药株式会社 由Rho激酶抑制剂和前列腺素类物质构成的青光眼治疗剂
AU2003280812A1 (en) * 2002-11-18 2004-06-15 Santen Pharmaceutical Co., Ltd. REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND Beta-BLOCKER
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
KR101333970B1 (ko) * 2005-05-19 2013-11-27 코와 가부시키가이샤 녹내장 예방 또는 치료제
JP4972551B2 (ja) * 2005-06-21 2012-07-11 興和株式会社 緑内障の予防又は治療剤
JP4972552B2 (ja) * 2005-07-12 2012-07-11 興和株式会社 緑内障を予防又は治療する薬剤
BRPI0614974A2 (pt) 2005-08-30 2010-12-14 Asahi Kasei Pharma Corp composto, medicamento, inibidor da fosforilaÇço da cadeia leve regulatària da miosina, inibidor da via rho/rho quinase, e, mÉtodo para tratamento terapÊutico e/ou profilÁtico de glaucoma
WO2007050783A2 (en) 2005-10-26 2007-05-03 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
JP5235887B2 (ja) 2006-09-20 2013-07-10 アエリー ファーマシューティカルズ インコーポレイテッド Ｒｈｏキナーゼ阻害剤
US8071779B2 (en) 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8415372B2 (en) 2007-02-27 2013-04-09 Asahi Kasei Pharma Corporation Sulfonamide compound
CN101622243B (zh) 2007-02-28 2013-12-04 旭化成制药株式会社 磺酰胺衍生物
CN101313926B (zh) * 2007-05-30 2012-12-26 中央研究院 转录调控物组合物
KR101246392B1 (ko) 2007-07-02 2013-03-21 아사히 가세이 파마 가부시키가이샤 술폰아미드 화합물 및 그 결정
US8207195B2 (en) 2008-06-26 2012-06-26 Inspire Pharmaceuticals, Inc. Method for treating neurological and neuropathic diseases using rho kinase inhibitor compounds
US8410147B2 (en) 2008-06-26 2013-04-02 Inspire Pharmaceuticals, Inc. Method for treating diseases associated with alterations in cellular integrity using Rho kinase inhibitor compounds
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
CA2929545C (en) 2009-05-01 2019-04-09 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
CA2805242A1 (en) * 2010-07-19 2012-01-26 Inspire Pharmaceuticals, Inc. Bifunctional rho kinase inhibitor compounds, composition and use
WO2012043891A1 (ja) 2010-09-30 2012-04-05 ダイトーケミックス株式会社 眼疾患処置薬
TW202126308A (zh) * 2011-02-04 2021-07-16 日商興和股份有限公司 青光眼治療劑與高眼壓症治療劑
KR102074020B1 (ko) * 2012-07-13 2020-02-05 산텐 세이야꾸 가부시키가이샤 술폰아미드 화합물의 조합
US9339496B2 (en) 2012-07-13 2016-05-17 Santen Pharmaceutical Co., Ltd. Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist
ES2852377T3 (es) 2013-03-15 2021-09-13 Aerie Pharmaceuticals Inc Sales dimesilato de 4-(3-amino-1-(isoquinolin-6-ilamino)-1-oxopropan-2-il)bencilo, sus combinaciones con prostaglandinas y el uso de las mismas en el tratamiento de trastornos oculares
EP4046628A1 (en) 2013-10-31 2022-08-24 Allergan, Inc. Prostamide-containing intraocular implants and methods of use thereof
KR20150090445A (ko) 2014-01-29 2015-08-06 주식회사 이노칩테크놀로지 적층칩 소자
SG11201704735WA (en) * 2014-12-12 2017-07-28 Kowa Co Composition
CN107921036A (zh) * 2015-05-29 2018-04-17 优势医疗公司 用于减少视力丧失的组合物和方法
CN108601355B (zh) 2015-11-17 2021-03-30 爱瑞制药公司 制备激酶抑制剂及其中间体的方法
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
WO2018045091A1 (en) 2016-08-31 2018-03-08 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
CA3057872A1 (en) 2017-03-31 2018-10-04 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
EP3730143A4 (en) 2017-12-21 2021-08-18 Santen Pharmaceutical Co., Ltd. OMIDENEPAG COMBINATION
CN111479568A (zh) * 2017-12-21 2020-07-31 参天制药株式会社 司培前列素与Rho激酶抑制剂的组合药物
US10696638B2 (en) 2017-12-26 2020-06-30 Industrial Technology Research Institute Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same
CN108815169A (zh) * 2018-05-23 2018-11-16 中南大学湘雅医院 一种前列腺素类物质组合得到有效的青光眼治疗剂
US11427563B2 (en) 2018-09-14 2022-08-30 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
WO2021182596A1 (ja) * 2020-03-13 2021-09-16 興和株式会社 上眼瞼溝深化改善剤

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2945008C2 (de) * 1979-11-08 1981-08-20 Lück, Werner, 4290 Bocholt Stützelement für medizinische Lagerungszwecke
US4599353A (en) 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US4952581A (en) * 1987-04-03 1990-08-28 The Trustees Of Columbia University In The City Of New York Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure
ATE76750T1 (de) 1987-04-03 1992-06-15 Univ Columbia Anwendung eines prostaglandins in mischung mit einem adrenergischen blocker zur verminderung des augen-innendruckes.
CA1324129C (en) * 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandins of the f series
ES2052735T3 (es) 1987-09-18 1994-07-16 R Tech Ueno Ltd Un metodo para producir un agente hipotensor ocular.
CA1334168C (en) * 1988-04-26 1995-01-31 Louis M. De Santis Antiglaucoma compositions containing combinations of .alpha.-2 agonists and .beta. blockers
JPH02108U (ko) 1988-06-14 1990-01-05
WO1990002553A1 (en) * 1988-09-06 1990-03-22 Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
EP0868186B1 (en) * 1995-12-21 2005-03-02 Alcon Laboratories, Inc. Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ocular ischemia
NZ334613A (en) * 1996-08-12 2002-02-01 Welfide Corp Pharmaceutical agents comprising Rho kinase inhibitor
DE69932235T2 (de) * 1998-04-02 2007-06-14 Genentech, Inc., South San Francisco Behandlung von herzhypertrophie
JP4212149B2 (ja) 1998-06-11 2009-01-21 株式会社デ・ウエスタン・セラピテクス研究所 医薬
DE69927936T2 (de) * 1998-08-17 2006-06-29 Mitsubishi Pharma Corp. Präventiva/mittel zur glaukombehandlung
SE9803761D0 (sv) * 1998-11-04 1998-11-04 Synphora Ab Method to avoid increased iridial pigmentation during prostaglandin treatment
WO2000057914A1 (fr) * 1999-03-25 2000-10-05 Santen Pharmaceutical Co., Ltd. Agents permettant d'abaisser la tension oculaire
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
US20030018079A1 (en) 2000-11-13 2003-01-23 Richardson Helene Treatment
DE60211317T2 (de) 2001-03-23 2007-04-12 Bayer Corp. Rho-kinase inhibitoren
DK1370552T3 (da) 2001-03-23 2007-05-07 Bayer Pharmaceuticals Corp Rho-kinase-inhibitorer
WO2002100833A1 (fr) 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Inhibiteurs de rho kinase
EP1455795A1 (en) * 2001-12-12 2004-09-15 Pharmacia Corporation Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
CN100425241C (zh) * 2002-08-29 2008-10-15 参天制药株式会社 由Rho激酶抑制剂和前列腺素类物质构成的青光眼治疗剂
AU2003280812A1 (en) * 2002-11-18 2004-06-15 Santen Pharmaceutical Co., Ltd. REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND Beta-BLOCKER
WO2004105757A2 (en) * 2003-05-29 2004-12-09 Schering Aktiengesellschaft Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy

Also Published As

Publication number Publication date
KR101160780B1 (ko) 2012-06-27
US20100063060A1 (en) 2010-03-11
EP2314299A1 (en) 2011-04-27
TW201032807A (en) 2010-09-16
EP1541151B1 (en) 2012-02-22
CN100425241C (zh) 2008-10-15
WO2004019951A1 (ja) 2004-03-11
CA2496797A1 (en) 2004-03-11
EP1541151A4 (en) 2007-07-18
JP5174777B2 (ja) 2013-04-03
TWI337881B (en) 2011-03-01
ES2382733T3 (es) 2012-06-13
KR101092048B1 (ko) 2011-12-12
KR20050057014A (ko) 2005-06-16
CA2496797C (en) 2012-01-10
US20050245509A1 (en) 2005-11-03
KR20110004920A (ko) 2011-01-14
EP1541151A1 (en) 2005-06-15
CN1684689A (zh) 2005-10-19
US20100041671A1 (en) 2010-02-18
TWI350170B (en) 2011-10-11
JP2009298808A (ja) 2009-12-24
US20120040994A1 (en) 2012-02-16
ATE546143T1 (de) 2012-03-15
TW200409654A (en) 2004-06-16

Similar Documents

Publication Publication Date Title
AU2003257588A1 (en) REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS
TW200626558A (en) Indazolone derivatives
TW200736223A (en) N-(pyridin-2-yl)-sulfonamide derivatives
GEP20125379B (en) 2 -pyridine carboxamide derivatives as sodium channel modulators
NO20051263L (no) Ny anvendelse av benzotiazolderivater
MXPA05001581A (es) Algunas imidazopiridinas novedosas y su uso.
SE0001899D0 (sv) New compounds
MY148108A (en) Medicaments for the treatment or prevention of fibrotic diseases
GEP20094780B (en) Prostaglandin nitrooxyderivatives
EP1283054A4 (en) MEDICAMENTS FOR TREATING THE COMPLICATIONS OF DIABETES AND NEUROPATHIES AND USE THEREOF
MXPA03008401A (es) Combinacion de brimonidina y timolol para uso oftalmico, topico.
HK1138265A1 (en) Materials and methods for treating coagulation disorders
TW200630364A (en) 2-amido-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
ECSP066878A (es) [hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa
CA2454976A1 (en) Therapeutic agent for glaucoma comprising compound having pi3 kinase inhibitory action as active ingredient
WO2006125194A3 (en) Piperazine derivatives and their uses as therapeutic agents
WO2006042478A8 (fr) Inhibiteurs de petites molecules de la protease principale des coronavirus, leur preparation et utilisation
AR061233A1 (es) Formulacion de liberacion prolongada de naltrexona
MY133107A (en) Use of pyrimidine derivatives for the prophylaxis and therapy of cerebral ischemia
AU2002332488A1 (en) R-bambuterol, its preparation and therapeutic uses
HRP20080255A2 (en) Use of cicletanine and other furopyridines for treatment of systolic predominant hypertension, isolated systolic hypertension, elevated pulse pressure and general hypertension
BR0209063A (pt) Medicamentos e kits de uso medicinal
WO2008032222A3 (en) Treatment of vertigo with acetyl-l-leucine
TW200503709A (en) Itching treating agent containing piperidine derivative as active ingredient
ID27253A (id) Penggunaan turunan-turunan kampotesin dengan toksisitas gastrointestinal yang tereduksi

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase